Concepedia

Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction

Jasper Tromp, Mohsin A.F. Khan, IJsbrand T. Klip, Sven Meyer, Rudolf A. de Boer, Tiny Jaarsma, Hans Hillege, Dirk J. van Veldhuisen, Peter van der Meer, Adriaan A. Voors

Journal of the American Heart Association · 2017 · 240 citations · 29 references

DOIFull text

Open access

Abstract

In HFpEF, inflammation and angiogenesis-mediated interactions are predominantly observed, while stretch-mediated interactions are found in HFrEF. The remodeling marker osteopontin and the angiogenesis marker neuropilin predicted outcome in HFpEF, but not in HFrEF.

References

29

Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction

Theophilus Owan, David O. Hodge, Regina M. Herges et al. · New England Journal of Medicine · 2006 · 4.2K citations

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

Salim Yusuf, Marc A. Pfeffer, Karl Swedberg et al. · The Lancet · 2003 · 2.9K citations

, , +7

Spironolactone for Heart Failure with Preserved Ejection Fraction

Bertram Pitt, Marc A. Pfeffer, Susan F. Assmann et al. · New England Journal of Medicine · 2014 · 2.6K citations · Full text

A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms

Xiaoyi Gao, Joshua Starmer, Eden R. Martin · Genetic Epidemiology · 2008 · 900 citations · Full text

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction

Rudolf A. de Boer, Dirk J. Lok, Tiny Jaarsma et al. · Annals of Medicine · 2010 · 582 citations · Full text